A VCP-specific inhibitor, VCP20, was found to prolong survival and improve bone destruction in a murine model of MM via disruption of NF-κB signaling in MM and osteoclast cells.205 VCP20 has yet to be evaluated in humans, however, other VCP inhibitors (CB-5083, CB-5339) have been clinically investigated over the years (Table 1). This evidence concerns the gene NFKB1 and Miyoshi myopathy.